ZA956412B - Mutant enterotoxin effective as a non-toxic oral adjuvant - Google Patents

Mutant enterotoxin effective as a non-toxic oral adjuvant

Info

Publication number
ZA956412B
ZA956412B ZA956412A ZA956412A ZA956412B ZA 956412 B ZA956412 B ZA 956412B ZA 956412 A ZA956412 A ZA 956412A ZA 956412 A ZA956412 A ZA 956412A ZA 956412 B ZA956412 B ZA 956412B
Authority
ZA
South Africa
Prior art keywords
oral adjuvant
toxic oral
effective
mutant enterotoxin
mutant
Prior art date
Application number
ZA956412A
Other languages
English (en)
Inventor
John D Clements
Bonny L Dickinson
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of ZA956412B publication Critical patent/ZA956412B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Dental Preparations (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
ZA956412A 1994-08-26 1995-08-01 Mutant enterotoxin effective as a non-toxic oral adjuvant ZA956412B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/296,848 US6019982A (en) 1994-08-26 1994-08-26 Mutant enterotoxin effective as a non-toxic oral adjuvant

Publications (1)

Publication Number Publication Date
ZA956412B true ZA956412B (en) 1996-03-11

Family

ID=23143827

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA956412A ZA956412B (en) 1994-08-26 1995-08-01 Mutant enterotoxin effective as a non-toxic oral adjuvant

Country Status (22)

Country Link
US (2) US6019982A (zh)
EP (1) EP0777490B1 (zh)
JP (1) JP3860208B2 (zh)
KR (1) KR100399258B1 (zh)
CN (1) CN1182868C (zh)
AT (1) ATE326231T1 (zh)
AU (1) AU709779B2 (zh)
BR (1) BR9508633A (zh)
CA (1) CA2198586C (zh)
CZ (1) CZ298131B6 (zh)
DE (1) DE69534992T2 (zh)
DK (1) DK0777490T3 (zh)
ES (1) ES2265148T3 (zh)
FI (1) FI120137B (zh)
HU (1) HU222985B1 (zh)
NO (1) NO317942B1 (zh)
NZ (1) NZ291262A (zh)
PL (1) PL182667B1 (zh)
PT (1) PT777490E (zh)
RU (1) RU2160606C2 (zh)
WO (1) WO1996006627A1 (zh)
ZA (1) ZA956412B (zh)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
WO1993018150A1 (en) * 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
DK0725653T3 (da) 1993-10-05 2004-10-11 Celltech Pharmaceuticals Ltd Vaccinepræparater
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
WO1996001273A1 (en) * 1994-07-01 1996-01-18 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
GB2324093A (en) * 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
AU7410798A (en) * 1996-11-29 1998-06-22 General Hospital Corporation, The Heterologous antigens in live cell V
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
JP2001510031A (ja) * 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
AU3089599A (en) * 1998-03-18 1999-10-11 Smithkline Beecham Corporation Production of purified mutant enterotoxin for use as an adjuvant
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
GB9819484D0 (en) * 1998-09-07 1998-10-28 Univ Bristol Therapeutic agents
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
EP1195162B1 (en) * 1999-03-03 2008-06-04 The Kitasato Institute Vaccine preparation containing fatty acid as a constituent
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
WO2001019998A1 (en) * 1999-09-15 2001-03-22 Mogam Biotechnology Research Institute Novel detoxified mutants of escherichia coli heat-labile enterotoxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
JP4889175B2 (ja) * 1999-10-18 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 感染性因子に対する免疫応答を刺激するための組成物および方法
DK1227837T3 (da) 1999-10-22 2008-09-15 Aventis Pasteur Fremgangsmåde til introduktion og/eller fremskyndelse af et immunrespons på et tumorantigen
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
WO2001085932A2 (en) 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
ES2284681T3 (es) 2000-08-25 2007-11-16 Aventis Pasteur Limited Epitopos de oligosacaridos del nucleo de lipopolisacaridos de maemophilus influenzae como vacunas para la prevencion de infecciones por haemophilus influenzae.
US7560484B2 (en) 2000-08-31 2009-07-14 The Kitasato Institute Vaccine preparation containing fatty acid as a constituent
US7527802B2 (en) * 2001-02-13 2009-05-05 The United States Of America As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
WO2002074244A2 (en) 2001-03-19 2002-09-26 Iomai Corporation Transcutaneous immunostimulation
CN1541111A (zh) 2001-06-07 2004-10-27 ���Ͽع����޹�˾ 作为佐剂的霍乱全毒素的突变形式
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
CA2458854A1 (en) * 2001-08-31 2003-03-06 Chiron Srl Helicobacter pylori vaccination
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
EP1531859A4 (en) * 2002-05-31 2005-12-07 Univ Jefferson COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT
WO2004020585A2 (en) * 2002-08-27 2004-03-11 Dow Agrosciences Llc Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
EP1581256A4 (en) * 2002-11-14 2006-06-07 Pfizer Prod Inc USE OF RMLT AS MARKER ANTIGEN FOR VACCINE AND AS SYNERGISTIC ADJUVANS WITH AMPY
US20060069052A1 (en) * 2003-02-14 2006-03-30 David Hone DNA vaccines that expresses mutant ADP-ribosyItransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
US20040171565A1 (en) * 2003-02-14 2004-09-02 David Hone DNA vaccines that expresses mutant ADP-ribosyltransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
WO2005019412A2 (en) 2003-05-20 2005-03-03 New York University Mucosal immunization to prevent prion infection
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
BRPI0414073A (pt) 2003-09-02 2006-10-24 Glaxosmithkline Biolog Sa método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
EP1708744A4 (en) * 2003-12-09 2009-07-15 Intercell Usa Inc GM1 Binding Dereficent Exotoxins for Use as Immunoinguarantees
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN100387719C (zh) * 2005-05-09 2008-05-14 中国农业科学院生物技术研究所 编码大肠杆菌热敏毒素基因及其表达载体和用途
WO2007028259A2 (en) * 2005-09-09 2007-03-15 Universität Zürich Antigens for vaccination against and detection of mycoplasma suis
WO2007091911A1 (fr) * 2006-02-09 2007-08-16 Institut Problem Pererabotki Uglevodorodov Sibirskogo Otdeleniya Rossiiskoi Akademii Nauk Sorbant, procédé de fabrication et procédé de séchage d'hydrocarbures
WO2007098607A1 (en) 2006-03-03 2007-09-07 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-sod1 mediated diseases
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
AU2007353789B2 (en) 2007-05-23 2014-05-22 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
ES2537094T3 (es) * 2007-07-18 2015-06-02 Development Center For Biotechnology Enterotoxina termolábil de E. coli mutada
DE102007037301A1 (de) * 2007-08-07 2009-02-12 BSH Bosch und Siemens Hausgeräte GmbH Hausgeräteanordnung
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
ES2534671T3 (es) 2007-09-11 2015-04-27 University Of Guelph Inmunógenos polisacáridos de la Clostridium difficile
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
WO2010002867A2 (en) * 2008-07-01 2010-01-07 The Goerge Washington University Multivalent antihelminthic vaccine
US7927586B2 (en) * 2008-07-08 2011-04-19 South Dakota State University Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli
US8758766B2 (en) 2008-12-24 2014-06-24 The Kingdom of The Netherlands, Represented by The Mininster of Health, Welfare and Sport, on Behalf of The Minster The National Institute of Public Health and The Environment Modified Streptococcus pneumoniae pneumolysin (PLY) polypeptides
TW201103980A (en) 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
US20140093556A1 (en) 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CN104379170B (zh) 2012-06-20 2017-05-03 国立大学法人东京大学 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
US10548970B2 (en) 2015-10-05 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rotavirus G9P[6] strain and use as a vaccine
EP3374383A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia BETA-AMYLOID EPITOPES AND ASSOCIATED ANTIBODIES
CN108350051A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中的N-末端表位及其构象选择性抗体
KR20180085736A (ko) 2015-11-09 2018-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CN110075290A (zh) * 2018-01-25 2019-08-02 吴夙钦 流感黏膜疫苗组合物及其制备方法与应用
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
IL101715A (en) * 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant

Also Published As

Publication number Publication date
DE69534992T2 (de) 2007-05-10
EP0777490B1 (en) 2006-05-17
NO970993D0 (no) 1997-03-04
NZ291262A (en) 1999-02-25
PT777490E (pt) 2006-10-31
EP0777490A1 (en) 1997-06-11
KR100399258B1 (ko) 2003-12-31
PL182667B1 (pl) 2002-02-28
DE69534992D1 (de) 2006-06-22
US6019982A (en) 2000-02-01
WO1996006627A1 (en) 1996-03-07
CZ298131B6 (cs) 2007-07-04
AU709779B2 (en) 1999-09-09
PL318930A1 (en) 1997-07-21
JPH10505059A (ja) 1998-05-19
ATE326231T1 (de) 2006-06-15
BR9508633A (pt) 1997-09-30
FI970799A (fi) 1997-04-24
CZ56297A3 (en) 1997-10-15
FI120137B (fi) 2009-07-15
RU2160606C2 (ru) 2000-12-20
CN1182868C (zh) 2005-01-05
ES2265148T3 (es) 2007-02-01
KR970705403A (ko) 1997-10-09
CN1164191A (zh) 1997-11-05
HUT77869A (hu) 1998-09-28
MX9701445A (es) 1998-05-31
AU3233795A (en) 1996-03-22
CA2198586C (en) 2010-10-12
CA2198586A1 (en) 1996-03-07
DK0777490T3 (da) 2006-09-18
NO970993L (no) 1997-04-25
HU222985B1 (hu) 2004-01-28
JP3860208B2 (ja) 2006-12-20
FI970799A0 (fi) 1997-02-26
US6440423B1 (en) 2002-08-27
EP0777490A4 (en) 1998-11-18
NO317942B1 (no) 2005-01-10

Similar Documents

Publication Publication Date Title
ZA956412B (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
ATE187078T1 (de) Nichttoxisches schleimhautadjuvans
DE69304521T2 (de) Impfstoff Adjuvans
HK1004060A1 (en) Oral vaccine comprising antigen surface-associated with red blood cells
AU2147992A (en) Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them
ES8608872A1 (es) Un metodo para preparar una composicion terapeutica a base de un extracto soluble en piridina y una endotoxina destosificada refinada.
SE9003198D0 (sv) Fish vaccine comprising a virulent, invasive bacterium
AU7788194A (en) Vaccine compositions
EP1438066A4 (en) IMMUNOGENIC COMPOSITIONS OF ENTIRE CELLS OF REACTIVE BACTERIA
HK1138516A1 (en) Parenteral vaccine formulations and uses thereof
HK1025220A1 (en) Novel saponin compositions and uses thereof
AR011592A1 (es) Metodo de creacion, o mantenimiento o para inducir una inmuno respuesta protectora o adaptativa a un virus hiv en un huesped
ES2051621A1 (es) Procedimiento de obtencion de vacuna frente a estafilococos.
RU96116250A (ru) Штамм pestivirus, используемый для изготовления лапинизированной вирус вакцины против классической чумы свиней